Arcadia Biosciences (NASDAQ:RKDA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note published on Sunday morning. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Arcadia Biosciences in a research report on Friday, April 5th.

Arcadia Biosciences Stock Performance

Shares of RKDA opened at $2.03 on Friday. The firm has a market cap of $2.76 million, a PE ratio of -0.14 and a beta of 0.60. The firm’s 50 day moving average price is $2.41 and its 200 day moving average price is $2.75. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $7.30.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings data on Thursday, March 28th. The basic materials company reported ($2.48) earnings per share for the quarter, beating the consensus estimate of ($2.68) by $0.20. The firm had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative return on equity of 81.56%. On average, sell-side analysts anticipate that Arcadia Biosciences will post -5.01 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.